Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Cash from Financing Activities (2018 - 2023)

Historic Cash from Financing Activities for Regenerative Medical Technology (RMTG) over the last 6 years, with Q4 2023 value amounting to -$300000.0.

  • Regenerative Medical Technology's Cash from Financing Activities fell 451964.89% to -$300000.0 in Q4 2023 from the same period last year, while for Sep 2025 it was -$300000.0, marking a year-over-year change of. This contributed to the annual value of -$309850.0 for FY2023, which is 139138.43% down from last year.
  • As of Q4 2023, Regenerative Medical Technology's Cash from Financing Activities stood at -$300000.0, which was down 451964.89% from -$9850.0 recorded in Q1 2023.
  • Over the past 5 years, Regenerative Medical Technology's Cash from Financing Activities peaked at $10.5 million during Q2 2021, and registered a low of -$300000.0 during Q4 2023.
  • In the last 5 years, Regenerative Medical Technology's Cash from Financing Activities had a median value of $67085.5 in 2019 and averaged $704962.9.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 870134.12% in 2021, then tumbled by 451964.89% in 2023.
  • Regenerative Medical Technology's Cash from Financing Activities (Quarter) stood at $71801.0 in 2019, then grew by 11.42% to $80000.0 in 2020, then soared by 1148.3% to $998642.0 in 2021, then crashed by 100.65% to -$6494.0 in 2022, then crashed by 4519.65% to -$300000.0 in 2023.
  • Its last three reported values are -$300000.0 in Q4 2023, -$9850.0 for Q1 2023, and -$6494.0 during Q4 2022.